11 and 12. Drug properties and environmental factors affecting drug pharmacokinetics and drug pharmacodynamics & Factors from the human body affecting the drug pharmacokinetics and drug pharmacodynamics.

Physicochemical Properties Affecting Pharmacokinetics and Pharmacodynamics

1. Molecular Size and Structure

• Pharmacokinetics: Smaller molecules generally diffuse more easily through biological membranes, enhancing absorption and distribution. However, larger molecules may require specialized transport mechanisms, such as carrier proteins or endocytosis.
• Pharmacodynamics: The structure determines how well a drug fits into its target receptor, affecting its efficacy and potency. Additionally, stereoisomerism can influence binding affinity, where one enantiomer may be more active than the other (e.g., S-warfarin is more potent than R-warfarin).

2. Solubility

• Pharmacokinetics: Lipophilic (fat-soluble) drugs cross cell membranes more readily, facilitating absorption and distribution, while hydrophilic (water-soluble) drugs may be confined to the extracellular space. Moreover, drugs with both hydrophilic and lipophilic properties (amphiphilic) may have enhanced distribution and bioavailability.
• Pharmacodynamics: Solubility can influence the ability of the drug to reach and bind to its target receptor. For instance, poorly soluble drugs may require formulation strategies like nanoparticle delivery systems to improve efficacy.

3. Ionization State

• Pharmacokinetics: The degree of ionization affects a drug's ability to cross cell membranes. Non-ionized (uncharged) drugs are more readily absorbed, especially in environments that favor their neutral form (e.g., weak acids are better absorbed in the stomach, while weak bases are absorbed in the intestines). The Henderson-Hasselbalch equation helps predict ionization at different pH levels.
• Pharmacodynamics: Ionization can affect drug binding to receptors and enzymes, influencing the drug's efficacy. Certain ionized drugs may exhibit stronger interactions with charged receptor sites, altering their pharmacological activity.

4. Protein Binding

• Pharmacokinetics: Drugs bound to plasma proteins (e.g., albumin, α1-acid glycoprotein) are not readily available for distribution or excretion. Only the free (unbound) fraction is pharmacologically active. Drug interactions can occur when highly protein-bound drugs compete for binding sites, increasing free drug levels and potentially leading to toxicity.
• Pharmacodynamics: High protein binding can reduce the concentration of the drug at the target site, affecting its therapeutic effect. In hypoalbuminemia (e.g., in liver disease), reduced protein binding can increase drug potency, necessitating dose adjustments.

5. Stability

• Pharmacokinetics: Chemical stability affects a drug's shelf life and how it is metabolized in the body. Unstable drugs may degrade before reaching their target. Factors such as pH, temperature, and humidity can influence drug degradation. Some drugs require special formulations (e.g., enteric coatings for acid-sensitive drugs like omeprazole).